Rethink Cell Therapy: How Lipid Nanoparticles Enable Next-Gen Delivery

By Reshma Kapatrala, Samuel Clarke, Jeffrey Lam, and Paula Marcus, Cytiva

Cell therapy is reshaping the treatment landscape for cancer, autoimmune diseases, and genetic disorders, but its promise hinges on overcoming manufacturing hurdles—especially in gene delivery. While electroporation and viral vectors remain the most common methods, both come with limitations in scalability, cost, and cell viability. Lipid nanoparticles (LNPs) are emerging as a compelling alternative, offering gentler delivery of RNA payloads with improved consistency and integration into manufacturing workflows. Their versatility also allows for combination strategies with viral vectors, opening new possibilities for persistent gene expression and targeted editing. As developers seek to accelerate timelines and reduce costs, understanding where LNPs fit into the gene delivery ecosystem is key.

Access the full piece to explore how rethinking delivery methods can unlock new therapeutic opportunities and drive innovation in cell therapy manufacturing.